Interventions for lower extremity peripheral artery disease

[1]  Marc P. Bonaca,et al.  Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) , 2017, Circulation.

[2]  Khalid Yusoff,et al.  Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. , 2017, Lancet.

[3]  B. Derubertis,et al.  Atherectomy-Associated Complications in the Southern California Vascular Outcomes Improvement Collaborative. , 2017, Annals of vascular surgery.

[4]  J. Alsac,et al.  Stenting or Surgery for De Novo Common Femoral Artery Stenosis. , 2017, JACC. Cardiovascular interventions.

[5]  L. Norgren,et al.  A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization: A TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) Initiative. , 2017, Circulation.

[6]  R. Giugliano,et al.  Long-term Low-Density Lipoprotein Cholesterol–Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study , 2017, JAMA cardiology.

[7]  J. Deeks,et al.  BAlloon versus Stenting in severe Ischaemia of the Leg-3 (BASIL-3): study protocol for a randomised controlled trial , 2017, Trials.

[8]  D. Rybin,et al.  Endovascular treatment of the common femoral artery in the Vascular Quality Initiative , 2017, Journal of vascular surgery.

[9]  H. Lawall,et al.  Efficacy and Safety of Alprostadil in Patients with Peripheral Arterial Occlusive Disease Fontaine Stage IV: Results of a Placebo Controlled Randomised Multicentre Trial (ESPECIAL). , 2017, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[10]  S. Hoeks,et al.  Angiosome‐directed revascularization in patients with critical limb ischemia , 2017, Journal of vascular surgery.

[11]  L. Fleisher,et al.  2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2017, Journal of the American College of Cardiology.

[12]  P. Ponikowski,et al.  Cardiovascular Efficacy and Safety of Bococizumab in High‐Risk Patients , 2017, The New England journal of medicine.

[13]  H. Yokoi,et al.  Drug‐eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease , 2017, Journal of vascular surgery.

[14]  Freya J. I. Fowkes,et al.  Peripheral artery disease: epidemiology and global perspectives , 2017, Nature Reviews Cardiology.

[15]  J. Mills.  The application of the Society for Vascular Surgery Wound, Ischemia, and foot Infection (WIfI) classification to stratify amputation risk. , 2017, Journal of vascular surgery.

[16]  R. Hendel,et al.  Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial. , 2017, Journal of the American College of Cardiology.

[17]  I. Baumgartner,et al.  Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease , 2017, Circulation.

[18]  H. Fujita,et al.  Clinical Outcomes of Pedal Artery Angioplasty for Patients With Ischemic Wounds: Results From the Multicenter RENDEZVOUS Registry. , 2017, JACC. Cardiovascular interventions.

[19]  K. Mahaffey,et al.  Ticagrelor Versus Clopidogrel in Symptomatic Peripheral Artery Disease , 2017, The New England journal of medicine.

[20]  Qingbo Xu,et al.  Mesenchymal stem cells and vascular regeneration , 2017, Microcirculation.

[21]  L. Karanth,et al.  Lumbar sympathectomy techniques for critical lower limb ischaemia due to non-reconstructable peripheral arterial disease. , 2016, The Cochrane database of systematic reviews.

[22]  Shenming Wang,et al.  Drug-eluting balloon versus standard percutaneous transluminal angioplasty in infrapopliteal arterial disease: A meta-analysis of randomized trials. , 2016, International journal of surgery.

[23]  R. Seetharam,et al.  Administration of Adult Human Bone Marrow‐Derived, Cultured, Pooled, Allogeneic Mesenchymal Stromal Cells in Critical Limb Ischemia Due to Buerger’s Disease: Phase II Study Report Suggests Clinical Efficacy , 2016, Stem cells translational medicine.

[24]  F. Moll,et al.  Lack of Evidence for Dual Antiplatelet Therapy after Endovascular Arterial Procedures: A Meta-analysis. , 2016, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[25]  S. Assmann,et al.  Design and Rationale of the Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST‐CLI) Trial , 2016, Journal of the American Heart Association.

[26]  Rahul S. Patel.  Team Approach to Critical Limb Ischemia Care and Research. , 2016, Techniques in vascular and interventional radiology.

[27]  L. Niklason,et al.  Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials , 2016, The Lancet.

[28]  L. Miller,et al.  Percutaneous Transluminal Angioplasty in Patients With Infrapopliteal Arterial Disease: Systematic Review and Meta-Analysis , 2016, Circulation. Cardiovascular interventions.

[29]  M. Dake,et al.  Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery , 2016, Circulation.

[30]  E. Armstrong,et al.  Peripheral Artery Disease: Evolving Role of Exercise, Medical Therapy, and Endovascular Options. , 2016, Journal of the American College of Cardiology.

[31]  E. Wahlberg,et al.  The Risk of Disease Progression in Peripheral Arterial Disease is Higher than Expected: A Meta-Analysis of Mortality and Disease Progression in Peripheral Arterial Disease. , 2016, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[32]  F. Moll,et al.  Critical Limb Ischemia: Current Trends and Future Directions , 2016, Journal of the American Heart Association.

[33]  R. G. Statius van Eps,et al.  Percutaneous Transluminal Angioplasty and Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia (PADI) Trial , 2016, Circulation. Cardiovascular interventions.

[34]  J. Deeks,et al.  Bypass versus angio plasty in severe ischaemia of the leg - 2 (BASIL-2) trial: study protocol for a randomised controlled trial , 2016, Trials.

[35]  Hong Wang,et al.  Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions: 24-Month Results of IN.PACT SFA. , 2015, Journal of the American College of Cardiology.

[36]  F. Moll,et al.  Bone Marrow derived Cell Therapy in Critical Limb Ischemia: A Meta-analysis of Randomized Placebo Controlled Trials. , 2015, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[37]  W. H. Hoffmann,et al.  Endovascular Revascularization and Supervised Exercise for Peripheral Artery Disease and Intermittent Claudication: A Randomized Clinical Trial. , 2015, JAMA.

[38]  G. Spolverato,et al.  Outcomes of polytetrafluoroethylene-covered stent versus bare-metal stent in the primary treatment of severe iliac artery obstructive lesions. , 2015, Journal of vascular surgery.

[39]  Lee J. Markowitz,et al.  Effect of High-pressure, Intermittent Pneumatic Compression for the Treatment of Peripheral Arterial Disease and Critical Limb Ischemia in Patients Without a Surgical Option. , 2015, Wounds : a compendium of clinical research and practice.

[40]  Zhen Wang,et al.  Nonrevascularization-based treatments in patients with severe or critical limb ischemia. , 2015, Journal of vascular surgery.

[41]  C. Zeebregts,et al.  Editor's Choice--First Results of the Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) Technique for Aortoiliac Occlusive Disease. , 2015, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[42]  D. Slakey,et al.  The impact of statins on biological characteristics of stem cells provides a novel explanation for their pleiotropic beneficial and adverse clinical effects. , 2015, American journal of physiology. Cell physiology.

[43]  J. Mckinsey,et al.  One-Year Outcomes Following Directional Atherectomy of Infrapopliteal Artery Lesions , 2015, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[44]  F. Shebl,et al.  Distal embolization during lower extremity endovascular interventions , 2015, Journal of vascular surgery.

[45]  L. Norgren,et al.  An update on methods for revascularization and expansion of the TASC lesion classification to include below‐the‐knee arteries: A supplement to the inter‐society consensus for the management of peripheral arterial disease (TASC II): The TASC steering committee* , 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[46]  B. Modarai,et al.  Comparative Efficacy and Safety of Different Antiplatelet Agents for Prevention of Major Cardiovascular Events and Leg Amputations in Patients with Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis , 2015, PloS one.

[47]  L. Norgren,et al.  An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries , 2015, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[48]  D. Scheinert,et al.  Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. , 2015, The New England journal of medicine.

[49]  J. Freischlag,et al.  Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease. , 2015, Journal of vascular surgery.

[50]  L. Mauri,et al.  Wire-Interwoven Nitinol Stent Outcome in the Superficial Femoral and Proximal Popliteal Arteries: Twelve-Month Results of the SUPERB Trial , 2015, Circulation. Cardiovascular interventions.

[51]  Marc P. Bonaca,et al.  Pharmacological treatment and current management of peripheral artery disease. , 2015, Circulation research.

[52]  E. Amsterdam,et al.  Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia , 2015, Vascular medicine.

[53]  W. Yiu,et al.  Primary stenting in femoropopliteal occlusive disease - what is the appropriate role? , 2015, Circulation journal : official journal of the Japanese Circulation Society.

[54]  J. Massaro,et al.  Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study. , 2015, Journal of the American College of Cardiology.

[55]  Eld,et al.  Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). , 2015, Journal of the American College of Cardiology.

[56]  M Hassan Murad,et al.  Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. , 2015, Journal of vascular surgery.

[57]  J. Cooke,et al.  Effect of physical activity assessment on prognostication for peripheral artery disease and mortality. , 2015, Mayo Clinic proceedings.

[58]  F. Neumann,et al.  Stent Placement vs. Balloon Angioplasty for Popliteal Artery Treatment , 2015, Journal of Endovascular Therapy.

[59]  A. Algra,et al.  Effect of Repetitive Intra-Arterial Infusion of Bone Marrow Mononuclear Cells in Patients With No-Option Limb Ischemia: The Randomized, Double-Blind, Placebo-Controlled Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intra-arterial Supplementation (JUVENTAS) Trial , 2015, Circulation.

[60]  F. Vermassen,et al.  Primary stenting is nowadays the gold standard treatment for TASC II A & B iliac lesions: the definitive MISAGO 1-year results. , 2014, The Journal of cardiovascular surgery.

[61]  F. Vermassen,et al.  Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. , 2014, Journal of the American College of Cardiology.

[62]  M. Koelemay,et al.  Significant savings with a stepped care model for treatment of patients with intermittent claudication. , 2014, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[63]  A. Gardner,et al.  Step‐Monitored Home Exercise Improves Ambulation, Vascular Function, and Inflammation in Symptomatic Patients With Peripheral Artery Disease: A Randomized Controlled Trial , 2014, Journal of the American Heart Association.

[64]  S. Spiliopoulos,et al.  Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial. , 2014, JACC. Cardiovascular interventions.

[65]  J. Mckinsey,et al.  Lower extremity revascularization using directional atherectomy: 12-month prospective results of the DEFINITIVE LE study. , 2014, JACC. Cardiovascular interventions.

[66]  K. Katsanos,et al.  Atherectomy of the femoropopliteal artery: a systematic review and meta-analysis of randomized controlled trials. , 2014, The Journal of cardiovascular surgery.

[67]  Yan Liu,et al.  Clinical Effectiveness of Gene Therapy on Critical Limb Ischemia , 2014, Vascular and endovascular surgery.

[68]  R. Larson,et al.  Cilostazol is associated with improved outcomes after peripheral endovascular interventions. , 2014, Journal of vascular surgery.

[69]  I. Casella,et al.  Arm vein as an alternative autogenous conduit for infragenicular bypass in the treatment of critical limb ischaemia: a 15 year experience. , 2014, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[70]  Shenming Wang,et al.  Percutaneous transluminal angioplasty versus primary stenting in infrapopliteal arterial disease: a meta-analysis of randomized trials. , 2014, Journal of vascular surgery.

[71]  F. Biancari,et al.  Angiosome-targeted lower limb revascularization for ischemic foot wounds: systematic review and meta-analysis. , 2014, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[72]  D. Bandyk,et al.  Therapeutic angiogenesis for critical limb ischemia. , 2014, Seminars in vascular surgery.

[73]  J. Stevens,et al.  Cost-Effectiveness of Cilostazol, Naftidrofuryl Oxalate, and Pentoxifylline for the Treatment of Intermittent Claudication in People With Peripheral Arterial Disease , 2014, Angiology.

[74]  G. Lip,et al.  Treatment of hypertension in peripheral arterial disease. , 2013, The Cochrane database of systematic reviews.

[75]  Satinder Singh,et al.  Angiographic characteristics of femoropopliteal in‐stent restenosis: Association with long‐term outcomes after endovascular intervention , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[76]  T. Mackenzie,et al.  Growing Impact of Restenosis on the Surgical Treatment of Peripheral Arterial Disease , 2013, Journal of the American Heart Association.

[77]  Ryan J. Mays,et al.  Community walking programs for treatment of peripheral artery disease. , 2013, Journal of vascular surgery.

[78]  M. Verhaar,et al.  Mesenchymal stromal cells for the treatment of critical limb ischemia: context and perspective , 2013, Stem Cell Research & Therapy.

[79]  Igor Rudan,et al.  Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis , 2013, The Lancet.

[80]  T. Rand,et al.  Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). , 2013, Journal of the American College of Cardiology.

[81]  R. Forsythe,et al.  Clinical implications of the angiosome model in peripheral vascular disease. , 2013, Journal of vascular surgery.

[82]  M. Jaff,et al.  Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease. , 2013, Journal of vascular surgery.

[83]  F. Farrokhyar,et al.  Clinical Outcomes of 5358 Patients Undergoing Direct Open Bypass or Endovascular Treatment for Aortoiliac Occlusive Disease: A Systematic Review and Meta-Analysis , 2013, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[84]  A. Das,et al.  A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia , 2013, Journal of Translational Medicine.

[85]  L. Robertson,et al.  Prostanoids for intermittent claudication. , 2013, The Cochrane database of systematic reviews.

[86]  P. Sidhu,et al.  Randomized Trial of the SMART Stent versus Balloon Angioplasty in Long Superficial Femoral Artery Lesions: The SUPER Study , 2013, CardioVascular and Interventional Radiology.

[87]  D. Scheinert,et al.  A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. , 2012, Journal of the American College of Cardiology.

[88]  J. W. Stevens,et al.  Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication , 2012, The British journal of surgery.

[89]  J. Vos,et al.  DISCOVER: Dutch Iliac Stent trial: COVERed balloon-expandable versus uncovered balloon-expandable stents in the common iliac artery: study protocol for a randomized controlled trial , 2012, Trials.

[90]  P. Fitzgerald,et al.  Predictors of adverse clinical outcomes after successful infrapopliteal intervention , 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[91]  M. Uematsu,et al.  Angiographic restenosis and its clinical impact after infrapopliteal angioplasty. , 2012, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[92]  L. Robertson,et al.  Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. , 2012, The Cochrane database of systematic reviews.

[93]  F. Neumann,et al.  Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to bare-metal stents: long-term results from a randomized trial. , 2012, Journal of the American College of Cardiology.

[94]  C. Claussen,et al.  Management of peripheral arterial interventions with mono or dual antiplatelet therapy—the MIRROR study: a randomised and double-blinded clinical trial , 2012, European Radiology.

[95]  April E. Nedeau,et al.  Results for primary bypass versus primary angioplasty/stent for intermittent claudication due to superficial femoral artery occlusive disease. , 2012, Journal of vascular surgery.

[96]  D. Scheinert,et al.  Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. , 2012, Journal of vascular surgery.

[97]  J. Ehrman,et al.  Supervised Exercise Versus Primary Stenting for Claudication Resulting From Aortoiliac Peripheral Artery Disease: Six-Month Outcomes From the Claudication Exercise Versus Endoluminal Revascularization (CLEVER) Study , 2012, Circulation.

[98]  A. Davies,et al.  Chapter IV: Treatment of critical limb ischaemia. , 2011, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[99]  A. Davies,et al.  Chapter III: Management of cardiovascular risk factors and medical therapy. , 2011, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[100]  S. Burrows,et al.  A comparison of covered vs bare expandable stents for the treatment of aortoiliac occlusive disease. , 2011, Journal of vascular surgery.

[101]  M. Dake,et al.  Paclitaxel-Eluting Stents Show Superiority to Balloon Angioplasty and Bare Metal Stents in Femoropopliteal Disease: Twelve-Month Zilver PTX Randomized Study Results , 2011, Circulation. Cardiovascular interventions.

[102]  A. Algra,et al.  Differential propensity for major hemorrhagic events in patients with different types of arterial disease , 2011, Journal of thrombosis and haemostasis : JTH.

[103]  A. Caplan,et al.  The MSC: an injury drugstore. , 2011, Cell stem cell.

[104]  L. Norgren,et al.  Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia , 2011, The Lancet.

[105]  J. Mckinsey,et al.  Statin therapy is associated with superior clinical outcomes after endovascular treatment of critical limb ischemia. , 2011, Journal of vascular surgery.

[106]  J. Ricco,et al.  Early and late outcomes of percutaneous treatment of TransAtlantic Inter-Society Consensus class C and D aorto-iliac lesions. , 2011, Journal of vascular surgery.

[107]  B. Xie,et al.  Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. , 2011, Diabetes research and clinical practice.

[108]  K. Yeung,et al.  A systematic review of endovascular treatment of extensive aortoiliac occlusive disease. , 2010, Journal of vascular surgery.

[109]  M. Rotondo,et al.  Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. , 2010, Journal of vascular surgery.

[110]  B. Arslan,et al.  Outcomes of covered kissing stent placement compared with bare metal stent placement in the treatment of atherosclerotic occlusive disease at the aortic bifurcation. , 2010, Journal of vascular and interventional radiology : JVIR.

[111]  D. Newby,et al.  Randomized Controlled Trial of Dual Antiplatelet Therapy in Patients Undergoing Surgery for Critical Limb Ischemia , 2010, Annals of surgery.

[112]  Jeffrey A Carpenter,et al.  Nitinol Stent Implantation Versus Balloon Angioplasty for Lesions in the Superficial Femoral Artery and Proximal Popliteal Artery: Twelve-Month Results From the RESILIENT Randomized Trial , 2010, Circulation. Cardiovascular interventions.

[113]  J. Forbes,et al.  Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: An intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy. , 2010, Journal of vascular surgery.

[114]  J. Forbes,et al.  Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Analysis of amputation free and overall survival by treatment received. , 2010, Journal of vascular surgery.

[115]  M. Conte.  Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) and the (hoped for) dawn of evidence-based treatment for advanced limb ischemia. , 2010, Journal of vascular surgery.

[116]  J. Ruiz-Aragón,et al.  Efectividad de la simpatectomía lumbar en el tratamiento de la arteriopatía periférica oclusiva de miembros inferiores: revisión sistemática , 2010 .

[117]  R. Pande,et al.  A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication , 2010, Vascular medicine.

[118]  C. Claussen,et al.  Drug eluting stents versus PTA with GP IIb/IIIa blockade below the knee in patients with current ulcers--The BELOW Study. , 2010, The Journal of cardiovascular surgery.

[119]  R. Davies,et al.  Review of direct anatomical open surgical management of atherosclerotic aorto-iliac occlusive disease. , 2010, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[120]  P. Sandercock,et al.  Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. , 2010, JAMA.

[121]  J. Thörne,et al.  In situ saphenous vein bypass grafting - still first line treatment? A prospective study comparing surgical results between diabetic and non-diabetic populations. , 2010, VASA. Zeitschrift fur Gefasskrankheiten.

[122]  A. Ciapponi,et al.  Prostanoids for critical limb ischaemia. , 2010, The Cochrane database of systematic reviews.

[123]  E. Chavakis,et al.  Enhancing the outcome of cell therapy for cardiac repair: progress from bench to bedside and back. , 2010, Circulation.

[124]  Johannes Lammer,et al.  Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions , 2009, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[125]  N. Dash,et al.  Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells. , 2009, Rejuvenation research.

[126]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[127]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.

[128]  J. Berger,et al.  Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. , 2009, JAMA.

[129]  J. Habbema,et al.  What is the evidence on efficacy of spinal cord stimulation in (subgroups of) patients with critical limb ischemia? , 2009, Annals of vascular surgery.

[130]  W. Poncyljusz,et al.  The evaluation of primary stenting of sirolimus-eluting versus bare-metal stents in the treatment of atherosclerotic lesions of crural arteries , 2009, European Radiology.

[131]  Deepak L. Bhatt,et al.  Patients with peripheral arterial disease in the CHARISMA trial. , 2008, European heart journal.

[132]  C. Bing,et al.  Autologous transplantation of bone marrow mesenchymal stem cells on diabetic patients with lower limb ischemia , 2008 .

[133]  P. Robless,et al.  Cilostazol for peripheral arterial disease. , 2008, The Cochrane database of systematic reviews.

[134]  G. Moneta,et al.  Technical factors affecting autogenous vein graft failure: observations from a large multicenter trial. , 2007, Journal of vascular surgery.

[135]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[136]  L. Pedrini,et al.  Spinal cord stimulation for lower limb ischemic pain treatment. , 2007, Interactive cardiovascular and thoracic surgery.

[137]  S. Yusuf,et al.  Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. , 2007, The New England journal of medicine.

[138]  D. Scheinert,et al.  Nitinol Stent Implantation Versus Percutaneous Transluminal Angioplasty in Superficial Femoral Artery Lesions up to 10 cm in Length: The Femoral Artery Stenting Trial (FAST) , 2007, Circulation.

[139]  R. Langer,et al.  Ethnic-specific prevalence of peripheral arterial disease in the United States. , 2007, American journal of preventive medicine.

[140]  Rodney A. White,et al.  ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Intervent , 2006, Journal of vascular and interventional radiology : JVIR.

[141]  Christopher E. Attinger,et al.  Angiosomes of the Foot and Ankle and Clinical Implications for Limb Salvage: Reconstruction, Incisions, and Revascularization , 2006, Plastic and reconstructive surgery.

[142]  Johannes Lammer,et al.  Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. , 2006, The New England journal of medicine.

[143]  Scott A Berceli,et al.  Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. , 2006, Journal of vascular surgery.

[144]  J. Forbes,et al.  Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial , 2005, The Lancet.

[145]  J. Dunning,et al.  Is sympathectomy of benefit in critical leg ischaemia not amenable to revascularisation? , 2005, Interactive cardiovascular and thoracic surgery.

[146]  M. Donaldson,et al.  Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. , 2004, Journal of vascular surgery.

[147]  Stefanie Dimmeler,et al.  Profoundly Reduced Neovascularization Capacity of Bone Marrow Mononuclear Cells Derived From Patients With Chronic Ischemic Heart Disease , 2004, Circulation.

[148]  O. Ringdén,et al.  HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. , 2003, Experimental hematology.

[149]  W. Aronow,et al.  Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. , 2003, The American journal of cardiology.

[150]  P. Breslau,et al.  Polytetrafluoroethylene Femorotibial Bypass Grafting: 5-year Patency and Limb Salvage , 2003, Annals of vascular surgery.

[151]  S. Mondillo,et al.  Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. , 2003, The American journal of medicine.

[152]  O. Ringdén,et al.  Mesenchymal Stem Cells Inhibit and Stimulate Mixed Lymphocyte Cultures and Mitogenic Responses Independently of the Major Histocompatibility Complex , 2003, Scandinavian journal of immunology.

[153]  R. Peto,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[154]  F. Logerfo,et al.  A comparative study of alternative conduits for lower extremity revascularization: all-autogenous conduit versus prosthetic grafts. , 2000, Journal of vascular surgery.

[155]  Willard C. Johnson,et al.  A comparative evaluation of polytetrafluoroethylene, umbilical vein, and saphenous vein bypass grafts for femoral-popliteal above-knee revascularization: a prospective randomized Department of Veterans Affairs cooperative study. , 2000, Journal of vascular surgery.

[156]  U. Settmacher,et al.  Femorodistal PTFE bypass grafting for severe limb ischaemia: results of a prospective clinical study using a new distal anastomotic technique. , 2000, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[157]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[158]  A. AbuRahma,et al.  Prospective controlled study of polytetrafluoroethylene versus saphenous vein in claudicant patients with bilateral above knee femoropopliteal bypasses. , 1999, Surgery.

[159]  J. Isner,et al.  Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. , 1999, Circulation research.

[160]  Takayuki Asahara,et al.  Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.

[161]  Janet B. Dunbar,et al.  Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. , 1996, International journal of epidemiology.

[162]  M. Dennis.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .

[163]  R. H. Meier,et al.  Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. , 1994, Circulation.

[164]  M. Donaldson,et al.  Femoral-distal bypass with in situ greater saphenous vein. Long-term results using the Mills valvulotome. , 1991, Annals of surgery.

[165]  J. Edwards,et al.  Autogenous reversed vein bypass for lower extremity ischemia in patients with absent or inadequate greater saphenous vein. , 1987, American journal of surgery.

[166]  G. I. Taylor,et al.  The vascular territories (angiosomes) of the body: experimental study and clinical applications. , 1987, British journal of plastic surgery.

[167]  C. Rob,et al.  The Fate of the Claudicator , 1960, British medical journal.

[168]  V. Aboyans,et al.  2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed b , 2018, European heart journal.

[169]  M. Monami,et al.  Prostanoids in patients with peripheral arterial disease: A meta-analysis of placebo-controlled randomized clinical trials. , 2016, Journal of diabetes and its complications.

[170]  David G Armstrong,et al.  The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: risk stratification based on wound, ischemia, and foot infection (WIfI). , 2014, Journal of vascular surgery.

[171]  D. Scheinert,et al.  The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. , 2014, JACC. Cardiovascular interventions.

[172]  H. Hashimoto,et al.  Patients with peripheral artery disease who complete 12-week supervised exercise training program show reduced cardiovascular mortality and morbidity. , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[173]  J. Ricco,et al.  Long-term results of a multicenter randomized study on direct versus crossover bypass for unilateral iliac artery occlusive disease. , 2008, Journal of vascular surgery.

[174]  L. Norgren,et al.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). , 2007, Journal of vascular surgery.

[175]  J. H. van Bockel,et al.  Vein versus polytetrafluoroethylene in above-knee femoropopliteal bypass grafting: five-year results of a randomized controlled trial. , 2003, Journal of vascular surgery.

[176]  R. Rutherford,et al.  Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). , 2000, Journal of vascular surgery.

[177]  F. Logerfo,et al.  The use of arm vein in lower-extremity revascularization: results of 520 procedures performed in eight years. , 2000, Journal of vascular surgery.

[178]  S. Yusuf,et al.  Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53. , 2000 .

[179]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[180]  J. R. Schneider,et al.  The role of extraanatomic bypass in the management of bilateral aortoiliac occlusive disease. , 1994, Seminars in vascular surgery.

[181]  V. Bernhard,et al.  Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions. , 1986, Journal of vascular surgery.